Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia

Journal of Urology

Volumn 157, Issue 6, 1997, Pages 2171-2178

  Marks, Leonard S ^a   Partin, Alan W ^b   Gormley, Glenn J ^b   Dorey, Frederick J ^b   Shery, Erlinda D ^b   Garris, Joel B ^b   Subong, Eric N P ^b   Stoner, Elizabeth ^b   DeKernion, Jean B ^b  

^a Urological Sci Research Foundation   (United States)

^b NONE

Author keywords

biopsy; finasteride; prostate; prostatic hypertrophy

Indexed keywords

FINASTERIDE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0030900404     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)64707-4     Document Type: Article

References (43)

1. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperato-McGinley, J., Walsh, P. C., McConnell, J. D., Andriole, G. L., Geller, J., Bracken, B. R., Tenover, J. S., Vaughan, E. D., Pappas, F., Taylor, A., Binkowitz, B. and Ng, J.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. New Engl. J. Med., 327: 1185, 1992.
2. Stoner, E.: Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology, 43: 284, 1994.
3. Andersen, J. T., Ekman, P., Wolf, H., Beisland, H. O., Johansson, J. E., Kontturi, M., Lehtonen, T. and Tveter, K.: Can finastende reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology, 46: 631, 1995.
4. Boyle, P., Gould, A. L., Roehrborn, C. G.: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology, 48: 398, 1996.
5. Peters, C. A. and Barrack, E. R.: Androgen receptor localization in the human prostate: demonstration of heterogeneity using a new method of steroid receptor autoradiography. J. Steroid Biochem., 27: 533, 1987.
6. Huggins, C. and Stevens, R. A.: The effect of castration on benign hypertrophy of the prostate in man. J. Urol., 43: 705, 1940.
7. Peters, C. A. and Walsh, P. C.: The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist, on benign prostatic hyperplasia. New Engl. J. Med., 317: 599, 1987.
8. Forti, G., Salerno, R., Moneti, G., Zoppi, S., Fiorelli, G., Marinoni, T., Natali, A., Costantini, A., Serio, M., Martini, L. and Motta, M.: Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. J. Clin. Endocr. Metab., 68: 461, 1989.
9. Wendel, E. F., Brannen, G. E., Putong, P. B. and Grayhack, J. T.: The effect of orchiectomy and estrogens on benign prostatic hyperplasia. J. Urol., 108: 116, 1972.
10. Scott, W. W. and Wade, J. C.: Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J. Urol., 101: 81, 1969.
11. Laroque, P. A., Prahalada, S., Molon-Noblot, S., Cohen, S. M., Soper, K., Duprat, P., Peter, C. P. and van Zwieten, M. J.: Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors. Prostate, 27: 121, 1995.
12. Prahalada, S. R., Keenan, K. P., Hertzog, P. R., Gordon, L. R., Peter, C. P., Soper, K. A., van Zwieten, M. J. and Bokelman, D. L.: Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor. Urology, 43: 680, 1994.
13. Harada, M., Kinoshita, Y., Moriyama, M., Kondo, I., Nakahashi, M., Kumagai, H., Sasaki, H. and Hosaka, M.: Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA). Prostate, 25: 147, 1994.
14. Shapiro, E., Hartanto, V. and Lepor, H.: Quantifying the smooth muscle content of the prostate using double-immunoenzymatic staining and color assisted image analysis. J. Urol., 147: 1167, 1992.
15. Marks, L. S., Treiger, B., Dorey, F. J., Fu, Y. S. and deKernion, J. B.: Morphometry of the prostate: I. Distribution of tissue components in hyperplastic glands. Urology, 44: 486, 1994.
16. Barry, M. J., Fowler, F. J., Jr., O'Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K. and Cockett, A. T. K.: The American Urological Association symptom index for benign prostatic hyperplasia. J. Urol., 148: 1549, 1992.
17. Oesterling, J. E.: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J. Urol., 145: 907, 1991.
18. Greene, D. R., Egawa, S., Hellerstein, D. K. and Scardino, P. T.: Sonographic measurements of transition zone of prostate in men with and without benign prostatic hyperplasia. Urology, 36: 293, 1990.
19. Hodge, K. K., McNeal, J. E., Terris, M. K. and Stamey, T. A.: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J. Urol., 142: 71, 1989.
20. Wu, C. P. and Gu, F.-L.: The prostate in eunuchs. Prog. Clin. Biol. Res., 370: 249, 1991.
21. Oesterling, J. E., Epstein, J. I. and Walsh, P. C.: The inability of adrenal androgens to stimulate the adult human prostate: an autopsy evaluation of men with hypogonadotropic hypogonadism and panhypopituitarism. J. Urol., 136: 1030, 1986.
22. Imperato-McGinley, J., Guerrero, L., Gautier, T. and Peterson, R. E.: Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science, 186: 1213, 1974.
23. Peterson, R. E., Imperato-McGinley, J., Gautier, T. and Sturla, E.: Male pseudohermaphroditism due to steroid 5-alpha-reductase deficiency. Amer. J. Med., 62: 170, 1977.
24. Hunter, J.: Observations on certain parts of the animal oeconomy. In: The Complete Works of John Hunter. Edited by J. E. Palmer. Philadelphia: Haswell, Barrington, and Haswell, vol. 4, p. 68, 1841.
25. White, J. W.: The results of double castration in hypertrophy of the prostate. Ann. Surg., 22: 1, 1895.
26. Cabot, A. T.: The question of castration for enlarged prostate. Ann. Surg., 24: 265, 1896.
27. Lepor, H.: Alpha blockade for the treatment of benign prostatic hyperplasia. Urol. Clin. N. Amer., 22: 375, 1995.
28. Shapiro, E., Hartanto, V. and Lepor, H.: The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate, 21: 297, 1992.
29. Robert, M., Costa, P., Bressolle, F., Mottet, N. and Navratil, H.: Percentage area density of epithelial and mesenchymal components in benign prostatic hyperplasia: comparison of results between single biopsy, multiple biopsies and multiple tissue specimens. Brit. J. Urol., 75: 317, 1995.
30. Zlota, A., Sattar, A. A., Wespes, E., Noel, J. C. and Schulman, C. C.: Is one single prostate biopsy helpful for choosing a medical treatment of benign prostatic hyperplasia? A quantitative computerized morphometric study. Urology, 47: 329, 1996.
31. Desmond, P. M., Clark, J., Thompson, I. M., Zeidman, E. J. and Mueller, E. J.: Morbidity with contemporary prostate biopsy. J. Urol., 150: 1425, 1993.
32. Hammerer, P. and Huland, H.: Systematic sextant biopsies in 651 patients referred for prostate evaluation. J. Urol., 151: 99, 1994.
33. Lepor, H., Wang, B. and Shapiro, E.: Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology, 44: 199, 1994.
34. Berman, D. M. and Russell, D. W.: Cell-type-specific expression of rat steroid 5 alpha reductase isozymes. Proc. Nat. Acad. Sci., 90: 9359, 1993.
35. Levine, A. C., Wang, J. P., Ren, M., Eliashvili, E., Russell, D. W. and Kirshenbaum, A.: Immunohistochemical localization of steroid 5 alpha-reductase 2 in the human male fetal reproductive tract and adult prostate. J. Clin. Endocr. Metab., 81: 384, 1996.
36. Tewari, A., Shinohara, K. and Narayan, P.: Transition zone volume and transition zone ratio: Predictor of uroflow response to finasteride therapy in benign prostatic hyperplasia patients. Urology, 45: 258, 1995.
37. Tempany, C. M., Partin, A. W., Zerhouni, E. A., Zinreich, S. J. and Walsh, P. C.: The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. Prostate, 22: 39, 1993.
38. McNeal, J. E.: Regional morphology and pathology of the prostate. Am. J. Clin. Pathol., 49: 347, 1968.
39. McNeal, J. E.: Origin and evolution of benign prostatic enlargement. Invest. Urol., 15: 340, 1978.
40. Hammerer, P. G., McNeal, J. E. and Stamey, T. A.: Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J. Urol., 153: 111, 1995.
41. Cadeddu, J. A., Pearson, J. D., Lee, B. R., Landis, P., Partin, A. W., Epstein, J. I. and Carter, H. B.: Relationship between changes in prostate-specific antigen and the percent of prostatic epithelium in men with benign prostatic hyperplasia. Urology, 45: 795, 1995.
42. Marks, L. S., Dorey, F. J., Rhodes, T., Shery, E. D., Rittenhouse, H., Partin, A. W. and deKernion, J. B.: Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J. Urol., 156: 1035, 1996.
43. Ishida, J., Sugimura, K., Okizuka, H., Kaji, Y., Moriyama, M., Nagaoka, S., Mizutani, M. and Ishida, T.: Benign prostatic hyperplasia: value of MR imaging for determining histologic type. Radiology, 190: 329, 1994.